

# Els Van Nieuwenhuysen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/206551/publications.pdf>

Version: 2024-02-01

38  
papers

1,555  
citations

430874

18  
h-index

330143

37  
g-index

41  
all docs

41  
docs citations

41  
times ranked

3630  
citing authors

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature Genetics</i> , 2017, 49, 680-691.  | 21.4 | 356       |
| 2  | Identification of six new susceptibility loci for invasive epithelial ovarian cancer. <i>Nature Genetics</i> , 2015, 47, 164-171.  | 21.4 | 221       |
| 3  | Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. <i>International Journal of Epidemiology</i> , 2016, 45, 1619-1630.   | 1.9  | 111       |
| 4  | Shared heritability and functional enrichment across six solid cancers. <i>Nature Communications</i> , 2019, 10, 431.  | 12.8 | 88        |
| 5  | Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. <i>International Journal of Epidemiology</i> , 2016, 45, 884-895.  | 1.9  | 71        |
| 6  | High-grade serous tubo-ovarian cancer refined with single-cell RNA sequencing: specific cell subtypes influence survival and determine molecular subtype classification. <i>Genome Medicine</i> , 2021, 13, 111.       | 8.2  | 70        |
| 7  | Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. <i>Human Molecular Genetics</i> , 2015, 24, 5955-5964.  | 2.9  | 68        |
| 8  | Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. <i>Nature Communications</i> , 2015, 6, 8234.  | 12.8 | 63        |
| 9  | Methylome analysis of extreme chemoresponsive patients identifies novel markers of platinum sensitivity in high-grade serous ovarian cancer. <i>BMC Medicine</i> , 2017, 15, 116.                                      | 5.5  | 44        |
| 10 | The genetic landscape of 87 ovarian germ cell tumors. <i>Gynecologic Oncology</i> , 2018, 151, 61-68.  | 1.4  | 44        |
| 11 | Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer. <i>BMC Pharmacology &amp; Toxicology</i> , 2015, 16, 2.  | 2.4  | 33        |
| 12 | Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies. <i>Gynecologic Oncology</i> , 2020, 156, 308-314.   | 1.4  | 32        |
| 13 | Germline polymorphisms in an enhancer of <i>PSIP1</i> are associated with progression-free survival in epithelial ovarian cancer. <i>Oncotarget</i> , 2016, 7, 6353-6368.  | 1.8  | 29        |
| 14 | Network-Based Integration of GWAS and Gene Expression Identifies a <i>HOX</i> -Centric Network Associated with Serous Ovarian Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1574-1584. | 2.5  | 28        |
| 15 | Common variants at the <i>CHEK2</i> gene locus and risk of epithelial ovarian cancer. <i>Carcinogenesis</i> , 2015, 36, 1341-1353.   | 2.8  | 24        |
| 16 | Loss of 1p36.33 Frequent in Low-Grade Serous Ovarian Cancer. <i>Neoplasia</i> , 2019, 21, 582-590.   | 5.3  | 24        |
| 17 | Analysis of 108 patients with endometrial carcinoma using the PROMISE classification and additional genetic analyses for MMR-D. <i>Gynecologic Oncology</i> , 2020, 157, 245-251.                                      | 1.4  | 24        |
| 18 | The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients—results from the OVCAD study. <i>Tumor Biology</i> , 2016, 37, 3009-3016.   | 1.8  | 23        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Polygenic risk modeling for prediction of epithelial ovarian cancer risk. <i>European Journal of Human Genetics</i> , 2022, 30, 349-362.   | 2.8 | 23        |
| 20 | Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. <i>Human Genetics</i> , 2016, 135, 741-756.   | 3.8 | 19        |
| 21 | Ovarian cancer in children and adolescents: A rare disease that needs more attention. <i>Maturitas</i> , 2016, 88, 3-8.  | 2.4 | 19        |
| 22 | Genetic changes in nonepithelial ovarian cancer. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 871-882.   | 2.4 | 16        |
| 23 | The association between weight at birth and breast cancer risk revisited using Mendelian randomisation. <i>European Journal of Epidemiology</i> , 2019, 34, 591-600.   | 5.7 | 16        |
| 24 | Evaluating the ovarian cancer gonadotropin hypothesis: A candidate gene study. <i>Gynecologic Oncology</i> , 2015, 136, 542-548.   | 1.4 | 15        |
| 25 | Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study. <i>British Journal of Cancer</i> , 2018, 118, 1123-1129.  | 6.4 | 15        |
| 26 | Randomized CLIO/BGOG-ov10 trial of olaparib monotherapy versus physician's choice chemotherapy in relapsed ovarian cancer. <i>Gynecologic Oncology</i> , 2022, 165, 14-22.   | 1.4 | 14        |
| 27 | Comprehensive immunomolecular profiling of endometrial carcinoma: A tertiary retrospective study. <i>Gynecologic Oncology</i> , 2021, 162, 694-701.  | 1.4 | 9         |
| 28 | Radical hysterectomy without adjuvant radiotherapy in patients with cervix carcinoma FIGO 2009 IB1, with or without positive Sedlis criteria. <i>Gynecologic Oncology</i> , 2021, 162, 539-545.  | 1.4 | 7         |
| 29 | Decentralization of Next-Generation RNA Sequencing-Based MammaPrint® and Blueprint® Kit at University Hospitals Leuven and Curie Institute Paris. <i>Translational Oncology</i> , 2019, 12, 1557-1565.   | 3.7 | 6         |
| 30 | Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women. <i>Cancer Medicine</i> , 2019, 8, 2503-2513.  | 2.8 | 6         |
| 31 | Combination of weekly paclitaxel-carboplatin plus standard bevacizumab as neoadjuvant treatment in stage IB-IB cervical cancer. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 824-828.  | 2.5 | 6         |
| 32 | Experience with PlasmaJet® in debulking surgery in 87 patients with advanced-stage ovarian cancer. <i>Journal of Surgical Oncology</i> , 2021, 123, 1109-1114.   | 1.7 | 6         |
| 33 | No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 420-424.  | 2.5 | 3         |
| 34 | rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2473.   | 4.1 | 3         |
| 35 | Prospective non-interventional BELOVA/BGOG-ov16 study on safety of frontline bevacizumab in elderly patients with FIGO stage IV ovarian cancer: a study of the Belgian and Luxembourg Gynaecological Oncology Group. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 753-760. | 2.5 | 3         |
| 36 | Efficacy and safety of lucitanib + nivolumab in patients with advanced gynecologic malignancies: Phase 2 results from the LIO-1 study (NCT04042116; ENGOT-GYN3/AGO/LIO).. <i>Journal of Clinical Oncology</i> , 2022, 40, 5517-5517.   | 1.6 | 2         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | Features of durable response and treatment efficacy for capecitabine monotherapy in advanced breast cancer: real-world evidence from a large single-centre cohort. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 1041-1048. | 2.5 | 1         |
| 38 | EP877â€¦Intestinal (sub)obstruction in ovarian cancer patients: management, complications and survival. , 2019, , .  |     | 0         |